Specifically, compound 1 induces the expression of PRC2 enzyme complex in CML K562 cells [42] and deregulates phosphoinositide-3 kinase (PI3K) and Aurora kinase B activities [43]. The gene discussed is AURKB; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.